A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Carfilzomib identity.
Showing the latest 62 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 17, 2026.
PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT07715903 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was carfilzomib.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209330 with status AP dated 2021-06-11, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209422 with status AP dated 2019-09-09, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209425 with status AP dated 2020-03-16, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209526 with status AP dated 2026-07-20, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 211185 with status AP dated 2020-03-20, and names carfilzomib among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 202714 with status AP dated 2012-07-20, and names carfilzomib among the application record's active ingredients.
The Federal Register published notice 2012-10154, attributed to FDA and its parent HHS department, on 2012-04-27. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.
The Federal Register published notice 2014-11175, attributed to FDA and its parent HHS department, on 2014-05-15. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT01080391 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-21, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT01302392 at 2026-11-16T17:39:29.005Z. Its registry update date was 2017-05-02, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT01559935 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT01568866 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-11-14, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT01572480 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-03-10, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT01813227 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT01816971 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT01818752 at 2026-11-16T17:39:29.005Z. Its registry update date was 2019-08-26, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT02412878 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-23, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT02773030 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT02937571 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT02969837 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-01-16, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03029234 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-05-25, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03158688 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-05-09, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03275285 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-02-09, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03290950 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03412565 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-04-29, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03416374 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-27, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03859427 at 2026-11-16T17:39:29.005Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03934684 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT04191616 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-09-04, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT04430894 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT04756401 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT04925193 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT05497804 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was carfilzomib.
PubMed lists PMID 34647444 in Haematologica as Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-06-01 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 34774221 in The Lancet. Oncology as Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-11-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 35578151 in International journal of hematology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-05-17 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 36073950 in Japanese journal of clinical oncology as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-12-05 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 36372355 in Transplantation and cellular therapy as Randomized Controlled Trial, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-11-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 36375132 in Blood advances as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2023-04-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 36529145 in The Lancet. Haematology as Clinical Trial, Phase II, Equivalence Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-12-15 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 36642080 in The Lancet. Oncology as Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-01-12 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 36763537 in Blood advances as Clinical Trial, Phase II, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-10 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37479547 in Clinical lymphoma, myeloma & leukemia as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-07-03 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37584290 in Haematologica as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-02-01 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37632592 in Targeted oncology as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-08-26 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37691005 in British journal of haematology as Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-10 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 37717583 in The Lancet. Oncology as Journal Article, Multicenter Study, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-14 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38747414 in Polish archives of internal medicine as Journal Article, Clinical Trial, Phase III, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-14 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38811560 in Blood cancer journal as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-29 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 38938122 in British journal of haematology as Journal Article, Clinical Trial, Phase II, Multicenter Study, with publication-date metadata of 2024-06-28 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 39576965 in Blood advances as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2025-02-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 39638553 in European journal of haematology as Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 2024-12-05 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 40213696 in Frontiers in pharmacology as Journal Article, Review, with publication-date metadata of 2025-03-27 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 40397818 in Leukemia & lymphoma as Journal Article, Clinical Trial, Phase II, Multicenter Study, Clinical Trial, Phase I, with publication-date metadata of 2025-05-21 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 40672881 in HemaSphere as Journal Article, Review, with publication-date metadata of 2025-07-16 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 41134506 in International journal of hematology as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 41719502 in Blood advances as Journal Article, Clinical Trial, Phase II, Clinical Trial, Phase I, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 41942646 in Nature medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, with publication-date metadata of 2026-04-06 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.